Agennix views options, including partners or liquidation

11 April 2013

Germany and USA-based drug discovery firm Agennix AG (FSE: AGX) has provided an update regarding strategic options and its activities to further conserve cash, which could include a liquidation of the company. The company continues to pursue strategic opportunities, including potential combinations with other life sciences companies.

Last year, Agennix saw its shares plummet 74% to 0.49 euros after reporting disappointing results from a Phase III trials with its investigational non-small cell lung cancer (NSCLC) drug talactoferrin alfa, calling into question the company’s future (The Pharma Letter August 9, 2012). The drug has previously bombed in the sepsis indication.

Agennix also is continuing to take steps to further conserve cash, including an additional staff reduction, as well as plans to de-list from the Prime Standard sub-section of the Frankfurt Stock Exchange and list on the General Standard of the regulated market.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK